Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-14 |
2024-03 |
-0.61 |
-0.75 |
-0.14 |
-22.95% |
2024-02-28 |
2023-12 |
-0.44 |
-0.47 |
-0.03 |
-6.82% |
2024-02-28 |
2023-12 |
-0.44 |
N/A |
N/A |
N/A |
2023-11-08 |
2023-09 |
-0.46 |
N/A |
N/A |
N/A |
2023-11-08 |
2023-09 |
-0.46 |
-0.4 |
0.06 |
13.04% |
2023-08-08 |
2023-06 |
-0.47 |
-0.34 |
0.13 |
27.66% |
Date |
Firm |
Action |
From |
To |
2023-08-09 |
JP Morgan |
Downgrade |
Neutral |
Underweight |
2023-03-15 |
JP Morgan |
Upgrade |
|
Neutral |
2023-01-26 |
SVB Leerink |
Upgrade |
|
Market Perform |
2023-01-23 |
Morgan Stanley |
Upgrade |
|
Underweight |
2022-08-14 |
Morgan Stanley |
Upgrade |
|
Underweight |
2022-03-01 |
JP Morgan |
Upgrade |
|
Neutral |
Date |
Name |
Relation |
Quantity |
Description |
2022-11-13 |
BERGER FRANKLIN MILAN |
Director |
778.35K |
Sale |
2024-01-31 |
CORCORAN ANDREA J |
Chief Financial Officer |
670.21K |
Sale |
2024-01-31 |
FOSTER WAYNE CPA |
Officer |
20.86K |
Sale |
2020-11-02 |
HACK ANDREW A. F. |
Director |
0.00 |
Purchase |
2024-01-31 |
HAMMOND JANET MJ |
Officer |
35.36K |
Sale |
2024-01-31 |
HORGA MARIA ARANTXA |
Officer |
25.66K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
FMR, LLC |
8.50M |
31.78M |
10.19% |
2023-06-29 |
Blackrock Inc. |
7.71M |
28.83M |
9.24% |
2023-06-29 |
EcoR1 Capital, LLC |
7.00M |
26.16M |
8.39% |
2023-06-29 |
Vanguard Group Inc |
4.52M |
16.90M |
5.42% |
2023-06-29 |
Tang Capital Management, LLC |
3.03M |
11.32M |
3.63% |
2023-06-29 |
Bain Capital Life Sciences Investors, LLC |
2.49M |
9.30M |
2.98% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
2.25M |
8.43M |
2.70% |
2023-08-30 |
Fidelity Growth Company Fund |
1.99M |
6.69M |
2.39% |
2023-08-30 |
iShares Russell 2000 ETF |
1.74M |
5.84M |
2.08% |
2023-05-30 |
Fidelity Growth Company K6 Fund |
1.18M |
4.71M |
1.42% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.17M |
4.36M |
1.40% |
2023-08-30 |
iShares Russell 2000 Value ETF |
691.44K |
2.32M |
0.83% |